Onderzoeker
Robert Paridaens
- Disciplines:Laboratoriumgeneeskunde, Palliatieve zorg en zorg rond het levenseinde, Regeneratieve geneeskunde, Andere basiswetenschappen, Andere gezondheidswetenschappen, Verpleegkunde, Andere paramedische wetenschappen, Andere translationele wetenschappen, Andere medische en gezondheidswetenschappen
Affiliaties
- Laboratorium Experimentele Oncologie (Afdeling)
Lid
Vanaf1 okt 2005 → 30 sep 2017
Publicaties
11 - 20 van 124
- Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm(2016)
Auteurs: Lynn Jongen, Robert Paridaens, Beppe Floris, Hans Wildiers, Patrick Neven
Pagina's: 603 - 7 - Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients(2015)
Auteurs: Christof Vulsteke, Alena M Pfeil, Charlotte Maggen, Matthias Schwenkglenks, Ruth Pettengell, Thomas D Szucs, Diether Lambrechts, Anne-Sophie Dieudonné, Sigrid Hatse, Patrick Neven, et al.
Pagina's: 67 - 76 - Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients(2015)
Auteurs: Charlotte Maggen, Diether Lambrechts, Sigrid Hatse, Patrick Neven, Robert Paridaens, Hans Wildiers
Pagina's: 67 - 76 - Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens(2014)
Auteurs: Anneleen Lintermans, Dirk Vanderschueren, Johan Verhaeghe, Kathleen Van Asten, Annouschka Laenen, Robert Paridaens, Jaak Billen, Steven Pauwels, Pieter Vermeersch, Hans Wildiers, et al.
Pagina's: 2925 - 2931 - Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis(2014)
Auteurs: Benoit Beuselinck, Evelyne Lerut, Herlinde Dumez, Joost Berkers, Hendrik Van Poppel, Steven Joniau, Raymond Oyen, Robert Paridaens, Patrick Schöffski
Pagina's: E205 - E214 - Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib(2014)
Auteurs: Benoit Beuselinck, Diether Lambrechts, Steven Joniau, Evelyne Lerut, Robert Paridaens, Patrick Schöffski
Pagina's: 1413 - 1422 - Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel(2014)
Auteurs: Diether Lambrechts, Sigrid Hatse, Patrick Neven, Robert Paridaens, Hans Wildiers
Pagina's: 557 - 70 - Prognostic Impact of Baseline Serum C-Reactive Protein in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib(2014)
Auteurs: Benoit Beuselinck, Hendrik Van Poppel, Steven Joniau, Evelyne Lerut, Herlinde Dumez, Robert Paridaens, Ben Van Calster, Patrick Schöffski
Pagina's: 81 - 9 - A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI(2014)
Auteurs: Anneleen Lintermans, Kathleen Van Asten, Hans Wildiers, Annouschka Laenen, Robert Paridaens, Caroline Weltens, Johan Verhaeghe, Dirk Vanderschueren, Ann Smeets, Erik Van Limbergen, et al.
Pagina's: 109 - 116 - Aromatase inhibitors in the breast cancer clinic: focus on exemestane(2014)
Auteurs: Kathleen Van Asten, Patrick Neven, Anneleen Lintermans, Hans Wildiers, Robert Paridaens
Pagina's: R31 - R49